Beam Therapeutics (NASDAQ:BEAM) Stock Price Breaks Below 50-Day Moving Average – Here’s What Happened

Beam Therapeutics Inc. (NASDAQ:BEAM) shares passed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $25.45 and traded as low as $23.60. Beam Therapeutics shares last traded at $25.15, with a volume of 3,115,247 shares changing hands.

Beam Therapeutics News Summary

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Beam said its BEACON Phase 1/2 trial met its primary efficacy endpoint: patients were free of severe vaso-occlusive crises for at least 12 consecutive months. The study also met its primary safety and all secondary endpoints, including freedom from hospitalization for severe crises. Beam Therapeutics BEACON trial announcement
• Positive Sentiment: The results support Beam’s plan to submit a U.S. biologics license application for risto-cel as early as year-end 2026. If approved, the base-edited therapy could compete with existing sickle cell treatments Casgevy and Lyfgenia. Beam prepares FDA filing after pivotal success
• Positive Sentiment: HC Wainwright maintained its Buy rating and made modestly less-negative earnings estimates across several future periods, offering a secondary positive signal. These estimates were issued before the trial announcement. Beam Therapeutics analyst estimates
• Negative Sentiment: BEAM shares declined even as the trial news emerged. The supplied coverage noted the disconnect but did not identify a specific reason for the market’s reaction, so investors may be weighing the results against expectations and the remaining regulatory and commercialization steps. Beam shares fall despite trial win

Analyst Ratings Changes

Several research firms recently issued reports on BEAM. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Beam Therapeutics in a report on Thursday, October 15th. Wall Street Zen lowered shares of Beam Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, October 31st. William Blair raised shares of Beam Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Canaccord Genuity Group dropped their target price on shares of Beam Therapeutics from $79.00 to $78.00 and set a “buy” rating for the company in a research report on Wednesday, November 4th. Finally, Wedbush upped their target price on shares of Beam Therapeutics from $28.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $47.36.

Beam Therapeutics Trading Down 6.9%

The company has a market cap of $2.60 billion, a P/E ratio of -24.18 and a beta of 2.23. The business has a fifty day simple moving average of $25.45 and a 200 day simple moving average of $27.96. The company has a debt-to-equity ratio of 0.11, a quick ratio of 13.00 and a current ratio of 13.01.

Beam Therapeutics (NASDAQ:BEAM) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.11). The business had revenue of $0.31 million during the quarter, compared to the consensus estimate of $8.75 million. Beam Therapeutics had a negative return on equity of 32.76% and a negative net margin of 73.04%. The company’s quarterly revenue was down 96.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.10) earnings per share. Analysts anticipate that Beam Therapeutics Inc. will post -4.65 earnings per share for the current fiscal year.

Insider Activity at Beam Therapeutics

In related news, CEO John Evans sold 25,000 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $23.57, for a total value of $589,250.00. Following the completion of the transaction, the chief executive officer owned 1,047,205 shares in the company, valued at $24,682,621.85. This represents a 2.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 3.80% of the company’s stock.

Institutional Trading of Beam Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Versant Capital Management Inc raised its holdings in shares of Beam Therapeutics by 123.6% during the third quarter. Versant Capital Management Inc now owns 1,239 shares of the company’s stock valued at $30,000 after acquiring an additional 685 shares during the period. Northwestern Mutual Wealth Management Co. acquired a new stake in Beam Therapeutics during the second quarter valued at $43,000. Global Retirement Partners LLC grew its stake in shares of Beam Therapeutics by 297.3% in the 3rd quarter. Global Retirement Partners LLC now owns 1,490 shares of the company’s stock valued at $36,000 after buying an additional 1,115 shares in the last quarter. Hollencrest Capital Management bought a new stake in Beam Therapeutics in the first quarter worth approximately $43,000. Finally, Fulcrum Asset Management LLP bought a new stake in Beam Therapeutics in the third quarter worth $51,000. 99.68% of the stock is currently owned by institutional investors.

Beam Therapeutics Company Profile

Beam Therapeutics is a biotechnology company developing genetic medicines using base editing, a form of gene editing designed to make precise changes to DNA. Its platform includes base-editing technologies and delivery systems intended to address diseases by altering the genetic instructions involved in their development. The company’s research and development programs include potential treatments for genetic diseases, including sickle cell disease. Its work spans medicines made by editing a patient’s cells outside the body as well as approaches intended to deliver gene editing directly to cells in the body.